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Abstract 
Ageing in mammals remains an unsolved mystery. Anti-ageing is a recurring topic 
in the history of scientific research. Lifespan extension evoked by Sir2 protein in lower 
organisms has attracted a large amount of interests in the last decade. This review 
summarizes recent evidence supporting the role of a Sir2 mammalian homologue, 
SIRT1 (Silent information regulator T1), in regulating ageing and cellular senescence. 
The various signaling networks responsible for the anti-ageing and anti-senescence 
activity of SIRT1 have been discussed. In particular, a counter-balancing model 
involving the cross-talks between SIRT1 and AMP-activated protein kinase (AMPK), 
another stress and energy sensor, is suggested for controlling the senescence program in 
mammalian cells.    
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1. Cellular senescence 
Senescence, originating from the Latin word senex, refers to a physiological 
program towards permanent cell cycle arrest. The first evidence of cellular senescence 
dates back to fifty years ago when Hayflick and Moorhead observed that after a limited 
number of divisions, embryo-derived fibroblasts entered an irreversible state of growth 
arrest [1]. Similar phenomena have been subsequently observed in human hepatocytes, 
keratinocytes, lymphocytes, smooth muscle and endothelial cells [2-6], leading to the 
concept of 'Hayflick limit', i.e. the finite replicative life span or the restricted 
cumulative population doubling of somatic cells in vitro. Morphologically, senescent 
cells are characterized by cellular enlargement and flattening with a concomitant 
increase in the size of the nucleus and nucleoli, augmented number of lysosomes and 
Golgi, and the appearance of vacuoles in the cytoplasm [7].  
For a number of years, the occurrence of senescence in vivo has been questioned, 
due mainly to the lack of specific markers. In 1995, Dimri and colleagues reported that 
several types of human senescent cells expressed a β-galactosidase that was detectable 
by a histochemical assay at pH 6 [8]. An age-dependent increase in this 
senescence-associated β-galactosidase (SA-ß-Gal) staining was observed in human 
skin. On the other hand, this marker was absent in pre-senescent and quiescent 
fibroblasts, and terminally differentiated keratinocytes. Since then, other senescence 
biomarkers have been identified, including telomere attrition [9,10], active checkpoint 
kinase ATM [11], heterochromatin proteins [12], and the cyclin-dependent kinase 
(CDK) inhibitors p21CIP1 (p21), p16INK4a (p16) and p27KIP1 (p27) [13-16], most of 
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which are actively participated in pathways that affect cellular senescence. Using 
selective markers, an age-dependent increasing of senescent cells has been validated 
various mammal tissues in vivo [11,17-19]. Cellular senescence is now considered to 
the hallmark of mammalian ageing. 
The physiological roles of senescence remain controversial. In general, 
can be viewed as an alternative response program to cellular stresses and damages 
otherwise may cause programmed cell death [20]. When confronted with metabolic 
hyperglycemia) and/or environmental stressors (e.g. oxidative stress), a self-protective 
mechanism of senescence may be initiated to halt the energy-consuming process of 
proliferation (Figure 1). However, a feedback-regulation should be in place to prevent 
cellular senescence from becoming irreversible (as is the case with terminal ageing of 
the organism), which, most of the time is independent of the initial stress conditions. 
The duration of cell survival in the non-dividing state after cessation of proliferation 
also a characteristic of longevity [21]. The fate of senescent cells in the living 
is largely unknown. The persistent presence of senescent cells can exert adverse 
on tissue functions, thus representing a pivotal underlying cause of ageing-related 
dysfunctions and diseases [22]. For example, in healthy postnatal tissues, the 
endothelial cells (referring to those line the inner surface of blood vessels) are mostly 
quiescent and rarely proliferate. In response to vascular injury, tissue ischemia, or 
other stress conditions, a remarkable phenotypic plasticity allows them to proliferate 
rapidly. However, their regenerative capacities declines progressively and coincides 
with the development of senescence [23]. Senescent endothelial cells in vascular 
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lesions release less available nitric oxide for vasodilator regulation, and become 
pro-inflammatory, pro-thrombotic and pro-atherosclerotic, which accelerate the 
development of cardiovascular diseases [24,25].  
In addition to acting as a barrier of unlimited cell growth and division, senescence 
functions as a tumor suppressive mechanism to restrict excessive cell growth. 
Senescent cells are present in pre-malignant tissues [26]. Escaping from senescence, 
or immortality, is important for malignant transformation [26-29]. However, the 
additional levels of complexity suggest that senescence functions as a biological 
'double edged sword' during tumorigenesis. On the one hand, it prevents activated 
oncogenes from initiating a clone of neoplastic cells and limit the replicative capacity 
of an incipient tumor cell [30,31]. On the other hand, although senescent cells 
themselves cannot become neoplastic, they promote the growth of nearby 
preneoplastic cells and in this way may contribute to the age-related increase in tumor 
incidence [32,33].  
 
2. Sirtuins - the longevity regulator 
Sirtuins are a family of NAD+-dependent protein deacetylases that exert multiple 
cellular functions by interacting with, and deacetylating a wide range of signaling 
molecules, transcription factors, histones and enzymes [34-36]. Sir2 (silent 
information regulator 2), the first gene discovered in this family, was originally shown 
to regulate transcriptional silencing at cell-mating loci, telomeres, and ribosomal DNA 
(rDNA) in yeast, through deacetylation of the epsilon-amino groups of lysines in the 
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amino-terminal domains of histones [37-42]. The anti-ageing effects of Sir2 was 
firstly demonstrated by Kaeberlein et al, who showed that the integration of extra 
copies of Sir2 extended lifespan up to 30% in S. cerevisiae [43]. Similar effects of 
Sir2 on lifespan extension were subsequently observed in C. elegans and Drosophila 
melanogaster [44-47].  
Sirtuins are highly conserved during the evolution from bacteria to humans. In 
mammals, the family is represented by seven members assigned as SIRT1-7, which 
share the catalytic domain of ~275 amino acids with Sir2 [48-51]. SIRT1-7 show 
diverse cellular localizations. SIRT6 and SIRT7 are localized in the nucleus, while 
SIRT3, SIRT4 and SIRT5 reside in the mitochondria. [51]. SIRT1 and SIRT2 shuttle 
between the cytoplasm and the nucleus. Mammalian sirtuins have been implicated in 
a wide range of biological processes, including metabolism, cell survival, 
development, chromatin dynamics and DNA repair. SIRT1 is the mammalian ortholog 
most highly related to Sir2. Protein expression and transcription levels of SIRT1 
decline with ageing in animals and human tissues, including lung, fat, heart and blood 
vessels [52-54]. Sirtuins have attracted considerable interest because of their role as 
the longevity regulator and their therapeutic potentials for the prevention/treatment of 
ageing-associated medical complications, in particular cardiovascular diseases, 
diabetes and neurodegenerative disorders.  
In 1935, McCay and co-workers reported that long-term caloric restriction without 
malnutrition almost doubled lifespan in rats [55]. This lifespan-extending effect of 
caloric restriction has been confirmed in a wide range of organisms ranging from 
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yeast to rodents, and primates [56-60]. These observations lead to the concept that 
caloric restriction regulates lifespan by reducing the metabolic rate and thus 
diminishing the accumulation of macromolecule damage over time. In higher 
organisms, caloric restriction is the only non-genetic intervention capable of 
promoting longevity and reducing the incidence of age-related disorders, such as 
diabetes, cardiovascular disease, and cancer. Both Sir2 and SIRT1 have been 
implicated in the anti-ageing activity of caloric restriction. Decreasing the expression 
of Sir2 blocks the lifespan-extending effect of caloric restriction in S. cerevisiae and 
Drosophila [46,61]. Likewise, in rodents, caloric restriction stimulates SIRT1 
expression in a variety of tissues, including brain, visceral fat, kidney and liver [56]. 
Mice lacking SIRT1 fail to show an increased activity in response to caloric 
restriction [62]. By contrast, elevation of SIRT1 expression results in a beneficial 
phenotype resembling that of caloric restriction [63-65]. Despite these suggestive 
findings, there is yet no foolproof evidence that mammalian sirtuins are either 
indispensible or sufficient to lifespan extension in response to caloric restriction. In 
fact, the available evidence suggests that sirtuins mediate the anti-ageing effects of 
caloric restriction largely by regulating cellular energy metabolism in ways that 
directly benefit normal physiology [66-70].  
 
3. Sirtuins and senescence in mammalian cells 
In yeast, senescence is characterized by the accumulation of extrachomosomal 
rDNA circles (ERCs), which occurs in mother cells as they go through successive cell 
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divisions [71]. The Sir2 protein acts as a transcriptional silencer to suppress ERC 
formation, and as a consequence, increases longevity. The first evidence that sirtuins 
regulate mammalian cellular senescence was provided by Langley and colleagues, 
using the primary mouse embryonic fibroblasts as a model system [72]. SIRT1 
antagonizes premature cellular senescence, induced by pro-myelocytic leukemia 
protein, by interacting with and deacetylating p53. Subsequently, the anti-senescence 
effects of SIRT1 have been demonstrated in other cell types, including human cancer 
cells (breast cancer MCF-7, lung cancer H1299 and prostate cancer cells) [73,74], 
human diploid fibroblasts [75] and a human umbilical vein endothelial cell line 
(HUVEC) [76-78]. In most of these studies, when the effects of SIRT1 are prevented 
with specific pharmacological inhibitors or siRNA, a premature senescence-like 
phenotype can be observed. Conversely, overexpression or activation of SIRT1 
prevents both stress- and replication-induced cellular senescence. In HUVECs, 
cellular senescence occurs in parallel with an increased expression of plasminogen 
activator inhibitor-1(PAI-1) and a decrease in that of endothelial nitric oxide synthase 
(eNOS). SIRT1 exerts protective effects against endothelial dysfunction by preventing 
stress-induced premature senescence and deranged expression of PAI-1 and eNOS 
[76]. Cilostazol, a selective cAMP phosphodiesterase 3 inhibitor, exerts protective 
effects against endothelial senescence and dysfunction through upregulation of SIRT1, 
whereas sirolimus and everolimus induce endothelial senescence involving 
down-regulation of SIRT1 [77,78]. The latter studies suggest that p53 might be of the 
utmost importance in mediating the senescence signaling and the protective effect of 
9 
 
SIRT1. By contrast, it is not conclusive whether or not eNOS activation is directly 
involved in the anti-senescence activity of SIRT1, although the bioavailability of 
nitric oxide is impaired when SIRT1 is down-regulated [76]. Nevertheless, the 
increase in eNOS expression caused by caloric restriction is associated with 
mitochondrial biogenesis and enhanced expression of SIRT1 [79], whereas SIRT1 
deacetylates and activates eNOS [80], indicating that a positive feedback mechanism 
exists between these two signaling molecules.  
Endothelial regeneration is essential to maintain the functionality of the 
vasculature, in particular after mechanical endothelial injury and ischemia or during 
wound healing [81]. SIRT1 is highly expressed in the vasculature and regulates the 
proliferative activity of endothelial cells during tissue regeneration [82,83]. It has been 
implicated in the regeneration and proliferation of endothelial progenitor cells (EPCs) 
[83,84]. Exposure to high glucose accelerates EPC senescence and decreases EPC 
number, which is accompanied by a reduced SIRT1 expression and activity. 
Knockdown of SIRT1 with siRNA results in diminished EPC angiogenesis and 
increased senescence. SIRT1 controls the angiogenic activity of endothelial cells via a 
deacetylation-dependent inactivation of forkhead box O transcription factors 1 
(FoxO1), a crucial negative transcriptional regulator of blood vessel development 
[82,85,86]. The acetylation of FoxO1 in EPC is increased significantly following 
exposure to high glucose. Resveratrol reduces, whereas inhibitors of SIRT1 
(nicotinamide and suramine) potentiate the acetylation [83]. SIRT1 also deacetylates 
FoxO3 and/or FoxO4, attenuating FoxO-induced apoptosis and potentiating 
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FoxO-induced cell-cycle arrest [87-89]. While the implications of these FoxO 
modifications are still uncertain, it appears overall that deacetylation of FoxO proteins 
by SIRT1 promotes cell survival under stress conditions.  
During the process of replicative senescence in primary porcine aortic endothelial 
cells, both mRNA and protein expressions of SIRT1 are progressively decreased [53]. 
Overexpression of SIRT1 stimulates proliferation and prevents senescence by 
targeting the tumor suppressor kinase LKB1. In these cells, LKB1 promotes cellular 
senescence and retards endothelial proliferation through activation of AMPK, a 
master regulator of energy metabolism. SIRT1 is activated by increases in 
NAD/NADH ratio [90,91], whereas AMPK senses AMP/ATP levels through its 
upstream kinase LKB1 [92,93]. A cross-regulation of these two pivotal energy- and 
stress-sensor pathways has been implied in the context of endothelial ageing [23]. The 
endothelium-specific elevation of SIRT1 activity protects mice from developing 
drug-induced premature vascular senescence [53]. There are presumably various 
interactions between the SIRT1 and AMPK pathways [94-97]. However, the precise 
connections between these two nutrient sensing enzymes in cellular senescence are 
largely uncharacterized and warrant further investigations.  
In addition to SIRT1, SIRT6, a mammalian sirtuin associated with 
heterochromatic regions and nucleoli [98], has also been implicated in the regulation 
of cellular senescence. Indeed, SIRT6 depletion in mice leads to premature cellular 
senescence and telomere dysfunction with end-to-end chromosomal fusions, a pattern 
resembling the defects observed in Werner syndrome, a human premature ageing 
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disease [99]. SIRT6 modulates genome stability by interacting with and deacetylating 
histone H3 at telometic chromatin [100]. It also regulates CtIP [C-terminal binding 
protein (CtBP) interacting protein] to facilitate DNA end resection at the 
double-strand breaks (DSB) [101]. Moreover, SIRT6 forms a macromolecular 
complex with DNA-PK [DNA-dependent protein kinase] and promotes DSB repair 
[102]. The NFκB RelA subunit is also regulated by SIRT6, which enhances the 
NFκB-dependent gene expression changes involved in cellular senescence [103]. 
Mechanisms other than these have also been suggested to mediate the regulatory 
effects of this protein on energy metabolism in enhancing insulin signaling and 
glucose uptake [104]. Effects of other sirtuins, in particular SIRT2 and SIRT7, on 
mammalian ageing have also been proposed [105-108]. However, the functional 
relationship among these members of the sirtuin family remains poorly understood at 
this stage.  
 
4. Anti-senescence activity of SIRT1 – focus on the cross-talks with AMPK 
signaling pathway 
SIRT1 elicits its various effects by regulating the acetylation/deacetylation status 
of a wide range of protein targets involved in heterochromatin silencing, cycle 
progression, cell survival and metabolism [72,88,91,109-112]. By binding with and 
deacetylating the target proteins, SIRT1 is able to regulate their activities, intracellular 
localizations, stabilities and posttranslational modifications. With respect to cellular 
senescence, the plethora of substrates that SIRT1 targets for deacetylation includes 
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p53, NFκB, PGC-1α [peroxisome proliferator-activated receptor-γ coactivator 1α], 
eNOS, mTOR and FoxOs (Figure 1). The tumor suppressor p53 is among the first 
non-histone substrates identified to be functionally involved in the anti-senescence 
activity of SIRT1 [72]. Activation of the p53-p21 pathway acts as a major mediator of 
cellular senescence [113]. Deacetylation of p53 by SIRT1 results in an inhibition of 
DNA damage- and stress-mediated cellular senescence [114]. NF-κB is a major 
culprit that mediates ageing-associated pro-inflammatory responses [115]. Oxidative 
stress and reactive oxygen species (ROS) production modulates the promoter binding 
activity of NF-κB, which promotes cellular senescence by transactivating the 
expressions of cell cycle regulators [116]. SIRT1 physically interacts with the 
RelA/p65 subunit of NFκB and inhibits the transactivation potential of this protein 
[112]. Mitochondrial function changes during cellular senescence lead to metabolic 
inefficiency and increased generation of ROS [117]. SIRT1 promotes mitochondrial 
functions and reduces the production of ROS through regulating the master controller 
of mitochondrial biogenesis, PGC-1α, and the eNOS- and nitric oxide-dependent 
pathway [118,119]. A number of SIRT1 targets, including mTOR and FoxOs, are 
coordinately involved in the process of autophagy, a housekeeping process for 
maintaining energy balance via self-digestion [120,121]. The extension of lifespan by 
SIRT1 has been linked to the efficient maintenance of autophagic degradation, either 
directly or indirectly through a downstream signaling network [122,123].  
Mammalian senescence is triggered by a complex signaling network involving the 
interactions of multiple proteins [19]. Unlike Sir2 in yeast, which functions 
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exclusively in the nucleoli and heterochromatic regions, nucleocytoplasmic shuttling 
of SIRT1 has been demonstrated in various mammalian cellular systems [98,124-127]. 
Thus, when attempting to unravel the molecular events upstream and downstream of 
the SIRT1 pathway in regulating cellular senescence, one has to consider searching 
far beyond the border of nucleus or any single cellular compartment, and cover not 
only long-term DNA damages and telomere shortening, but also short-term metabolic 
adaptations. In that context, the remainder of this article will attempt to elucidate the 
interplays between SIRT1 and LKB1/AMPK signaling, the two well-known stress 
resistance and longevity-regulating pathways. 
 
4.1 AMPK, LKB1 and cellular senescence 
AMPK is the primary regulator of cellular responses to reduced ATP levels and 
acts as a sensor to maintain the energy balance within a cell [128,129]. In general, 
activation of AMPK down-regulates synthetic pathways such as protein, fatty acid and 
cholesterol biosynthesis, yet switches on the catabolic pathways that generate ATP, 
such as fatty acid oxidation, glucose uptake and glycolysis. It achieves this not only 
through direct phosphorylation of a variety of key metabolic enzymes, but also by 
altering gene expressions in a tissue-specific manner [130,131]. Depending on the 
tissue types, the targeted genes include PGC-1α, the FoxO family of transcription 
factors, SREBP [sterol regulatory element binding protein] and ChREBP 
[carbohydrate response element binding protein]. AMPK is a trimeric serine/threonine 
protein kinase comprising a catalytic α subunit and non-catalytic β and γ subunits. 
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The α subunit contains an NH2-terminal catalytic kinase domain and a 
COOH-terminal regulatory domain to which the β and γ subunits bind. The γ subunits 
contain four tandem repeats of a sequence motif “CBS domain”, which represents the 
regulatory AMP- and ATP-binding sites of the AMPK complex. Stresses (e.g. 
metabolic poisoning, free radical production, heat-shock, hypoxia, or nutrient 
deprivation) that cause a rise in AMP/ATP ratio can activate AMPK, by facilitating 
phosphorylation of the α subunit at a specific residue (Thr172) located within the 
activation loop. This process can cause at least 50- to 100-fold activation of AMPK 
and is mediated by upstream kinases (AMPKK), one of which is the tumor suppressor 
LKB1 [92]. This complex regulatory system results in a superb sensitivity of AMPK 
to respond to even a very small change in AMP levels.  
LKB1 is a serine/threonine protein kinase possessing proliferation-inhibitory and 
anti-tumor activities. It was originally discovered as a tumor suppressor gene mutated 
in patients with Peutz-Jeghers syndrome, a dominantly inherited human disorder 
characterized by an increased predisposition to cancer [132,133]. Loss-of-function of 
LKB1 is frequently found in non-small cell lung carcinomas [134]. Inactivation of 
LKB1 has also been reported in pancreatic cancers, melanomas, prostate, endometrial 
and cervical cancers, papillary breast cancers, testicular cancers, as well as colon and 
gastric cancers [135-137]. Overexpression of LKB1 suppresses cancer cell growth by 
inducing a G1 cell cycle arrest [138,139]. LKB1 is not only considered to be a tumor 
suppressor kinase that regulates cell proliferation, but also actively involved in 
controlling cell motility, metabolism, polarity and senescence [140-142].  
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LKB1 mediates AMPK activation in response to various cellular stresses- and 
pharmacological agents [143-150]. While activation of LKB1/AMPK signaling 
protects cells against energy stress by maintaining energy homeostasis and ensuring a 
slow consumption of energy stores [151,152], this pathway can also cause cellular 
senescence, cell cycle arrest and apoptosis in eukaryotic systems [153,154]. In another 
word, a certain level of AMPK activation is beneficial, whereas over-activation may 
be destructive. For example, mild energy restriction promotes AMPK activation and 
triggers neurogenesis, whereas severe diet restriction-induced AMPK leads to 
neuroapoptosis, possibly due to insufficient cell resources to reverse AMP:ATP ratio 
[155]. LKB1 is significantly up-regulated in senescent primary endothelial cells and 
overexpression of this kinase induces senescence through AMPK activation in young 
cells [53]. LKB1 deficiency prevents culture-induced senescence in murine embryonic 
fibroblasts [156]. In senescent fibroblasts, AMP:ATP ratios are two to three folds 
higher than those in young fibroblasts, and senescence is accompanied by a marked 
elevation in AMPK activity [157,158]. In mice, caloric restriction down-regulates 
AMPK activity in the liver [159]. Activation of LKB1/AMPK and inhibition of 
mTOR contribute to the premature ageing phenotype of Zmpste24-/- mice [153]. 
AMPK hyper-activation has also been reported in the skeletal muscle and liver of old 
rodents [160,161]. In the aorta of old mice, LKB1 and phosphorylated AMPK(Thr172) 
levels are much higher than those of young mice [53]. The regulation of ageing by 
AMPK is evolutionarily preserved. In yeast, the AMPK homologue Snf1 is a pivotal 
regulator of glucose-related gene expression at times of low fuel availability [162]. 
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Snf1 is a heterotrimer composed of a catalytic α subunit (Snf1p) that phosphorylates 
target proteins at Ser/Thr residues, an activating γ subunit (Snf4p), and a β subunit 
(Sip1p, Sip2p, or Gal83). snf1 null mutants are viable, but are unable to grow on 
sucrose, galactose, maltose, melibiose or nonfermentable carbon sources and do not 
contain any detectable peroxisomes, whereas overproduction of Snf1p causes 
accelerated ageing [163]. Loss of Snf4p, an activator of Snf1p, extends generational 
life span whereas loss of Sip2p, a presumed repressor of the kinase, causes an 
accelerated ageing [164].  
In summary, these findings suggest that chronic activation of the LKB1-AMPK 
catabolic pathway may turn an originally pro-survival strategy into a pre-ageing 
mechanism and contribute to the progressive degeneration during cellular senescence.  
 
4.2 Reciprocal regulations of SIRT1 and LKB1/AMPK signaling in cellular 
senescence 
Interactions between SIRT1 and AMPK pathways occur in different types of 
tissues and cells [95,97,165-172]. In liver, while AMPK and SIRT1 may act in an 
autoregulatory loop to regulate lipid metabolism, their impacts on gluconeogenesis 
during fasting conditions appear to diverge [165]. In skeletal muscle, AMPK enhances 
SIRT1 activity by increasing cellular NAD+ levels [94,173], and this amplification of 
SIRT1 and its downstream signaling pathways is impaired in AMPK-deficient states 
[171]. In neuronal systems, resveratrol-stimulated AMPK activity depends on LKB1 
but does not require SIRT1 [174]. However, other results suggest that resveratrol 
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activates LKB1/AMPK signaling in both SIRT1-dependent and independent manners 
in HepG2 cells [95,175]. In HEK293 cells, over-expression of SIRT1 activates AMPK 
through LKB1 [96]. It should be noted that the regulations of growth, survival, energy 
metabolism and response to stresses in cancer tissues are very different from those of 
normal cells. Cells from SIRT1 knockout mice show either no change [174] or an 
increase in AMPK activity [97,176,177]. Taken in conjunction, the available evidence 
suggests that AMPK and SIRT1 are vital links in an orchestrated network controlling 
cellular homeostasis. Therefore, it is of great importance to understand the 
mechanisms by which they interact and the consequences of the cross-regulations 
under various conditions.  
In endothelial cells, LKB1- and AMPK-induced senescence can be prevented by 
increasing the levels of SIRT1 [53]. By contrast, inhibition of SIRT1 activity or 
over-expression of a dominant negative deacetylase mutant, SIRT1(H363Y), induces 
endothelial senescence and elevates the protein levels of LKB1, resulting in a 
hyperactivation of AMPK [53]. These observations demonstrate the link between the 
anti-senescence activity of SIRT1 and the deregulation of LKB1/AMPK signaling 
[23]. Under normal physiological conditions, LKB1 is constitutively active [131], 
which makes it necessary to have a counter-mechanism available to prevent persistent 
or exaggerated activation of AMPK signaling. The regulation by SIRT1 of LKB1 
protein stability represents such a counterbalancing mechanism (Figure 2). 
Deacetylation mediated by SIRT1 synergizes with the ubiquintination and degradation 
of LKB1 [53]. Because both acetylation and ubiquitination occur on lysine residues, 
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deacetylation of LKB1 by SIRT1 may control the accessibility of these residues for 
ubiquitination and thereby alter its stability in endothelial cells. However, how 
deacetylation affects the biological activities of LKB1 is incompletely understood. 
Structurally, LKB1 kinase domain is poorly related to other protein kinases. In 
particular, the NH2- and COOH-terminal non-catalytic regions of LKB1 possess no 
identifiable functional domains. LKB1 shuttles between the nucleus and the cytoplasm 
[178]. When LKB1 is forced to remain in the cytoplasm by disruption of the nuclear 
localization signal, it retains full growth-suppression activity in a kinase-dependent 
manner [139]. It is highly possible that acetylation/deacetylation of specific residues 
by SIRT1 affect the intracellular localization, protein stability and/or protein-protein 
interactions of LKB1 in primary endothelial cells. Several other molecules involved in 
regulating senescence, including p53 and FoxOs, are also modulated by reversible 
acetylation and targeted by SIRT1 [72,179]. Changes in lysine acetylation may 
represent an important mechanism integrating metabolic and stress signals to govern 
cellular senescence and ageing. 
Cell cycle regulation by AMPK is mediated by inhibition of the TSC2-mTOR 
(mammalian target of rapamycin) pathway as well as up-regulation of the p53-p21 
axis [180,181] (Figure 2). The mTOR pathway is a major controller of protein 
biosynthetic processes. Blockage of this pathway induces protein degradation through 
autophagy and the ubiquitin-proteasome system [131]. Premature ageing activates a 
systemic metabolic response involving induction of autophagy [153]. Actually, the 
physiological ageing process is associated with a declined efficiency of autophagic 
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degradation [121]. Although both SIRT1 and AMPK are implicated in the regulation 
of autophagy [176,182,183], the detailed interactions and the involvement of mTOR 
or other signaling molecules, such as FoxOs, NFκB and p53, remain to be elucidated. 
Opposing effects of the two signaling molecules have been reported in relation to p53 
regulation. Persistent activation of AMPK leads to accelerated p53-dependent cellular 
senescence [180], whereas SIRT1 antagonizes p53-induced cellular senescence 
through promoting its deacetylation [72]. LKB1 acts as an upstream kinase for PTEN 
(phosphatase and tensin homologue), which overcomes growth/survival signaling 
from the PI3K/Akt pathway [184]. The balance between LKB1-AMPK and PI3K/Akt 
pathways may determine cell growth or death in response to the nutritional status and 
stress [185]. The cross-talks between SIRT1 and AMPK in controlling senescence 
could also converge at the level of PI3K/Akt signaling [53].  
Unlike in the metabolic organ skeletal muscle, AMPK does not affect the NAD+ 
biosynthetic enzyme, NAMPT [nicotinamide phosphoribosyltransferase], in 
endothelial cells [53]. Moreover, NAMPT expression is not different in senescent 
cells from that of young cells. These findings, however, cannot exclude other 
mechanisms that may be involved in the regulation of SIRT1 by AMPK, such as those 
at the posttranscriptional levels (Figure 2). For example, SIRT1 mRNA levels are 
regulated by the RNA binding protein HuR and by microRNA, which repress SIRT1 
protein expression in response to different stress conditions [186-188]. Depending on 
the upstream signal, HuR causes SIRT1 mRNA to be either stabilized or degraded. 
During the progression of cellular senescence, the mRNA and protein levels of SIRT1 
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decrease progressively [53]. AMPK activation causes premature fibroblast senescence 
through a mechanism that involves HuR [157,189]. Moreover, AMPK inhibits the 
transport of HuR to the cytoplasm and thus blocks its ability to stabilize and enhance 
the expression of target mRNAs [189]. HuR levels are lower in senescent cells, and 
the over-expression of HuR restores a “younger” phenotype, whereas a reduction in 
HuR expression accentuates the senescent appearance [190]. Taken in conjunction, 
these studies are consistent with a role of HuR, possibly involving AMPK, in 
regulating the mRNA levels of SIRT1 during the process of replicative senescence.   
 
5. Concluding remarks 
Energy metabolism and metabolic regulators play pivotal roles in controlling 
longevity and cellular senescence. SIRT1 and LKB1/AMPK are the two key energy 
sensor systems regulating cell survival, proliferation and senescence. While acute 
activation of the LKB1/AMPK catabolic pathway permits a rapid adaption or 
resistance to external and internal stresses, sustained stimulation of the same 
pathway leads the cells toward a condition of irreversible senescence, which is 
detrimental to normal physiological functions. The anti-ageing activity of SIRT1 is 
achieved at least in part by fine-tuning the LKB1/AMPK pathway and preventing 
the transition of an originally pro-survival program into a pro-ageing mechanism, 
which results in systemic degeneration (Figure 3). This process is elegantly 
controlled by a complex network involving many signaling proteins, as well as by 
the ratios between low molecular weight metabolites (e.g. NAD/NADH and 
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AMP/ATP). Further studies on the reciprocal regulatory mechanisms and the 
unexplored pathways responsible for the dysregulated balance between SIRT1 and 
LKB1/AMPK signaling may provide important insights for temporal and 
quantitative control of the ageing process. 
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 Figures and legends: 
 
 
 
Figure 1. SIRT1 elicits the 
protein substrates that are critically involved in
such as oxidative stresses, DNA damage, mitochondrial biogenesis and 
autophagy.  
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Figure 2. Several potential molecular pathways are involved in cellular senescence 
caused by hyperactivated LKB1/AMPK signaling.  
 
 
  
  
Figure 3. A model represents the reciprocal regulations of SIRT1 and AMPK 
pathways in mammalian cellular 
to irreversible senescence is accompanied by a decreased SIRT1 expression and 
activity, and an augmented AMPK function. SIRT1 counter
targeting the upstream kinase LKB1. A possible feed
AMPK is suggested for further investigations
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senescence. The progression from pre-senescence 
-regulates AMPK through 
-back regulation of SIRT1 by 
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